Trevi Therapeutics, Inc. announced that it has entered into a securities purchase agreement with existing investor, New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc. in a private placement to issue 1,851,852 common shares, par value $0.001 per share at a price of $1.62 per share for gross proceeds of approximately $3,000,000 on October 15, 2021. The company will also issue accompanying warrants to purchase an aggregate of 3,703,704 shares of common stock. Of the warrants, warrants to purchase an aggregate of 1,851,852 shares of common stock will expire 3.5 years from the closing date and warrants to purchase an aggregate of 1,851,852 shares of common stock will expire seven years from the closing date. The warrants have an exercise price of $1.37 per share and became exercisable immediately upon issuance. The securities issued are pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Regulation D promulgated thereunder.